Trump’s Pharma Tariffs Spark Inflation Fears as Stocks and Currencies React
By:
Key Points:
- Pharmaceutical tariffs are increasing cost pressures and are likely to push inflation higher as supply chain costs begin to pass through to consumers.
- Large pharmaceutical companies may remain stable while small biotech firms face downside risk due to weaker pricing power and higher input costs.
- The US dollar may strengthen in the short term, while EUR/USD faces downside pressure and USD/CHF moves higher due to shifting capital flows.
The introduction of pharmaceutical tariffs by the Trump administration has created a new layer of uncertainty in the global markets with the prices of imports increasing and the pressure on costs starting to accumulate throughout supply chains. In my opinion, this policy change will lead to rising inflation and the growth of volatility in the equities and currency markets in the near future. The article discusses the impact of these tariffs on inflation, pharmaceutical stocks, healthcare ETFs and major currency pairs.